Contact this trialFirst, we need to learn more about you.
DNA Methyltransferase Inhibitor
DEC-C Pre-emptive Therapy for Myelodysplastic Syndrome
Recruiting1 awardPhase 1 & 2
Saint Louis, Missouri
This trial is testing whether a treatment of decitabine and cedazaridine (DEC-C) can decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with persistent mutations (molecular MRD). To detect molecular MRD, the investigators will use MyeloSeq-HD sequencing at Day 30 in post-transplant MDS patients. The investigators will treat patients with detectable molecular MRD with DEC-C to determine if pre-emptive, MRD-guided therapy with DEC-C decreases relapse rates and improves progression-free survival.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service